Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication. The setback will also delay plans to reach the clinic with another genetic medicine in its pipeline.
Gene-editing company Graphite Bio’s $238 million IPO was the biggest in biotech this week as it works toward human tests of a therapy that corrects the genetic mutation behind sickle cell disease. Elevation Oncology and Monte Rosa Therapeutics also made their stock market debuts, raising cash for clinical trials.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.